


## GUARDANT360 COVERS ALTERATIONS IN OVER 70 GENES RELEVANT TO MULTIPLE SOLID TUMORS INCLUDING MSI-HIGH

Point Mutations (SNVs) and Deletion Variants (Indels) (74 Genes)							Amplifications (18 Genes)		Fusions (6 Genes)
AKT1	ALK	APC	AR	ARAF	ARID1A	ATM	AR	BRAF	<b>ALK</b>
<b>BRAF</b>	<i>BRCA1</i>	<i>BRCA2</i>	<i>CCND1</i>	<i>CCND2</i>	<i>CCNE1</i>	<i>CDH1</i>	<i>CCND1</i>	<i>CCND2</i>	<b>FGFR2</b>
CDK4	CDK6	CDK12	<i>CDKN2A</i>	<i>CTNNB1</i>	<i>DDR2</i>	<b>EGFR</b>	<i>CCNE1</i>	<i>CDK4</i>	<b>FGFR3</b>
<b>ERBB2</b>	<i>ESR1</i>	<i>EZH2</i>	<i>FBXW7</i>	<i>FGFR1</i>	<i>FGFR2</i>	<i>FGFR3</i>	<i>CDK6</i>	<i>EGFR</i>	<b>NTRK1</b>
GATA3	<i>GNA11</i>	<i>GNAQ</i>	<i>GNAS</i>	<i>HNF1A</i>	<i>HRAS</i>	<i>IDH1</i>	<i>ERBB2</i>	<i>FGFR1</i>	<b>RET</b>
<i>IDH2</i>	<i>JAK2</i>	<i>JAK3</i>	<i>KIT</i>	<i>KRAS</i>	<i>MAP2K1</i>	<i>MAP2K2</i>	<i>FGFR2</i>	<i>KIT</i>	<b>ROS1</b>
MAPK1	<i>MAPK3</i>	<b>MET</b>	<i>MLH1</i>	<i>MPL</i>	<i>MTOR</i>	<i>MYC</i>	<i>KRAS</i>	<b>MET</b>	
<i>NF1</i>	<i>NFE2L2</i>	<i>NOTCH1</i>	<i>NPM1</i>	<i>NRAS</i>	<i>NTRK1</i>	<i>NTRK3</i>	<i>MYC</i>	<i>PDGFRA</i>	
PDGFRA	<i>PIK3CA</i>	<i>PTEN</i>	<i>PTPN11</i>	<i>RAF1</i>	<i>RB1</i>	<b>RET</b>	<i>PIK3CA</i>	<i>RAF1</i>	
<i>RHEB</i>	<i>RHOA</i>	<i>RIT1</i>	<i>ROS1</i>	<i>SMAD4</i>	<i>SMO</i>	<i>STK11</i>			
<i>TERT</i> <sup>†</sup>	<i>TP53</i>	<i>TSC1</i>	<i>VHL</i>						

Critical or all exons\* completely sequenced and all four major classes of alterations

NSCLC guideline-recommended genes shown in **bold** / \*Exons selected to maximize detection of known somatic mutations / <sup>†</sup> Includes *TERT* promoter region

## ctDNA DETECTION RATE BY CANCER TYPE WITH THE GUARDANT360 ASSAY<sup>1</sup>



CUP : Carcinoma of Unknown Primary

NSCLC : Non-small Cell Lung Cancer

Lung Adeno : Lung Adenocarcinoma

Cholangio : Cholangiocarcinoma

REFERENCES: 1. Zill et al. 2018 Clin Cancer Res / 2. Holdenrieder et al. Clin Cancer Res 2004; Bettegowda, et al. Sci Transl Med 2014

